250 related articles for article (PubMed ID: 33281815)
1. Development of a Broadly Protective, Self-Adjuvanting Subunit Vaccine to Prevent Infections by
Das S; Howlader DR; Zheng Q; Ratnakaram SSK; Whittier SK; Lu T; Keith JD; Picking WD; Birket SE; Picking WL
Front Immunol; 2020; 11():583008. PubMed ID: 33281815
[TBL] [Abstract][Full Text] [Related]
2. The protective effects of nasal PcrV-CpG oligonucleotide vaccination against Pseudomonas aeruginosa pneumonia.
Naito Y; Hamaoka S; Kinoshita M; Kainuma A; Shimizu M; Katoh H; Moriyama K; Ishii KJ; Sawa T
Microbiol Immunol; 2018 Dec; 62(12):774-785. PubMed ID: 30378708
[TBL] [Abstract][Full Text] [Related]
3. Outer Membrane Vesicles Displaying a Heterologous PcrV-HitA Fusion Antigen Promote Protection against Pulmonary Pseudomonas aeruginosa Infection.
Li P; Wang X; Sun X; Guan Z; Sun W
mSphere; 2021 Oct; 6(5):e0069921. PubMed ID: 34612675
[TBL] [Abstract][Full Text] [Related]
4. A Live
Aguilera-Herce J; García-Quintanilla M; Romero-Flores R; McConnell MJ; Ramos-Morales F
mSphere; 2019 Apr; 4(2):. PubMed ID: 30996108
[No Abstract] [Full Text] [Related]
5. Anti-PcrV IgY antibodies protect against Pseudomonas aeruginosa infection in both acute pneumonia and burn wound models.
Ranjbar M; Behrouz B; Norouzi F; Mousavi Gargari SL
Mol Immunol; 2019 Dec; 116():98-105. PubMed ID: 31634816
[TBL] [Abstract][Full Text] [Related]
6. Intradermal vaccination with a Pseudomonas aeruginosa vaccine adjuvanted with a mutant bacterial ADP-ribosylating enterotoxin protects against acute pneumonia.
Baker SM; Pociask D; Clements JD; McLachlan JB; Morici LA
Vaccine; 2019 Feb; 37(6):808-816. PubMed ID: 30638799
[TBL] [Abstract][Full Text] [Related]
7. Effect of Two Unique Nanoparticle Formulations on the Efficacy of a Broadly Protective Vaccine Against
Howlader DR; Das S; Lu T; Hu G; Varisco DJ; Dietz ZK; Walton SP; Ratnakaram SSK; Gardner FM; Ernst RK; Picking WD; Picking WL
Front Pharmacol; 2021; 12():706157. PubMed ID: 34483911
[No Abstract] [Full Text] [Related]
8. Efficacy comparison of adjuvants in PcrV vaccine against Pseudomonas aeruginosa pneumonia.
Hamaoka S; Naito Y; Katoh H; Shimizu M; Kinoshita M; Akiyama K; Kainuma A; Moriyama K; Ishii KJ; Sawa T
Microbiol Immunol; 2017 Feb; 61(2):64-74. PubMed ID: 28370521
[TBL] [Abstract][Full Text] [Related]
9. Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa.
Sawa T; Ito E; Nguyen VH; Haight M
Hum Vaccin Immunother; 2014; 10(10):2843-52. PubMed ID: 25483637
[TBL] [Abstract][Full Text] [Related]
10. Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice.
Moriyama K; Wiener-Kronish JP; Sawa T
Microbiol Immunol; 2009 Nov; 53(11):587-94. PubMed ID: 19903258
[TBL] [Abstract][Full Text] [Related]
11. In-Silico Analysis and Protective Efficacy of the PcrV Recombinant Vaccine against Pseudomonas Aeruginosa in the Burned and PA-Infected BALB/c Mouse Model.
Fakoor MH; Owlia P; Mousavi Gargari SL; Sabokbar A
Iran J Immunol; 2020 Jun; 17(2):121-136. PubMed ID: 32602466
[TBL] [Abstract][Full Text] [Related]
12. Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia.
Wu W; Huang J; Duan B; Traficante DC; Hong H; Risech M; Lory S; Priebe GP
Am J Respir Crit Care Med; 2012 Sep; 186(5):420-7. PubMed ID: 22723292
[TBL] [Abstract][Full Text] [Related]
13. Vaccination of mice with hybrid protein containing Exotoxin S and PcrV with adjuvants alum and MPL protects Pseudomonas aeruginosa infections.
Asadi Karam MR; Badmasti F; Ahmadi K; Habibi M
Sci Rep; 2022 Jan; 12(1):1325. PubMed ID: 35079054
[TBL] [Abstract][Full Text] [Related]
14. Rational Design of a Chimeric Derivative of PcrV as a Subunit Vaccine Against
Wan C; Zhang J; Zhao L; Cheng X; Gao C; Wang Y; Xu W; Zou Q; Gu J
Front Immunol; 2019; 10():781. PubMed ID: 31068928
[No Abstract] [Full Text] [Related]
15. A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models.
Warrener P; Varkey R; Bonnell JC; DiGiandomenico A; Camara M; Cook K; Peng L; Zha J; Chowdury P; Sellman B; Stover CK
Antimicrob Agents Chemother; 2014 Aug; 58(8):4384-91. PubMed ID: 24841258
[TBL] [Abstract][Full Text] [Related]
16. Immunization with 3-oxododecanoyl-L-homoserine lactone-r-PcrV conjugate enhances survival of mice against lethal burn infections caused by Pseudomonas aeruginosa.
Golpasha ID; Mousavi SF; Owlia P; Siadat SD; Irani S
Bosn J Basic Med Sci; 2015 May; 15(2):15-24. PubMed ID: 26042508
[TBL] [Abstract][Full Text] [Related]
17. The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa.
Kinoshita M; Kato H; Yasumoto H; Shimizu M; Hamaoka S; Naito Y; Akiyama K; Moriyama K; Sawa T
Hum Vaccin Immunother; 2016 Nov; 12(11):2833-2846. PubMed ID: 27454613
[TBL] [Abstract][Full Text] [Related]
18. Protective Efficacy of the Trivalent Pseudomonas aeruginosa Vaccine Candidate PcrV-OprI-Hcp1 in Murine Pneumonia and Burn Models.
Yang F; Gu J; Yang L; Gao C; Jing H; Wang Y; Zeng H; Zou Q; Lv F; Zhang J
Sci Rep; 2017 Jun; 7(1):3957. PubMed ID: 28638106
[TBL] [Abstract][Full Text] [Related]
19. Oligomerization of PcrV and LcrV, protective antigens of Pseudomonas aeruginosa and Yersinia pestis.
Gébus C; Faudry E; Bohn YS; Elsen S; Attree I
J Biol Chem; 2008 Aug; 283(35):23940-9. PubMed ID: 18583342
[TBL] [Abstract][Full Text] [Related]
20. Modified needle-tip PcrV proteins reveal distinct phenotypes relevant to the control of type III secretion and intoxication by Pseudomonas aeruginosa.
Sato H; Hunt ML; Weiner JJ; Hansen AT; Frank DW
PLoS One; 2011 Mar; 6(3):e18356. PubMed ID: 21479247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
